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Fifty million people in the US have hypertension. The
jNC-V guidelines provide treatment recommendations
for hypertension. These guidelines promote initiating
therapy with diuretics and beta blockers since these
agents have been shown to reduce hypertension-related
morbidity and mortality.
OBJECTIVES: To survey primary care physicians' anti-
hypertensive prescribing practices, their perceptions
about antihypertensive medication cost and safety and
the perceived impact of managed care.
METHODS: A direct mail survey was sent to a national
random sample of 500 office-based, primary care intern-
ists, family practitioners, and general practitioners.
RESULTS: Seventy-two percent of physicians reported
being aware of the jNC-V guidelines. Younger physicians
claimed to be more aware of and more likely to follow
jNC-V guidelines than older physicians. Only 25% of
physicians reported initiating treatment at systolic blood
pressures greater than 140 mm Hg as recommended by
the jNC-V guidelines. Diuretics were selected by 36% of
physicians, angiotensin-converting enzyme (ACE) inhibi-
tors by 35%, beta blockers by 16%, and calcium channel
blockers (CCBs) by 7% for initial antihypertensive treat-
ment. Up to 27% of physicians admitted not knowing the
cost of specific medications. Approximately half of physi-
cians reported that they and their patients were more
concerned about medication cost and safety today than
18 months ago. A greater number of younger physicians
than older physicians reported that managed care formu-
laries infringed upon their prescribing practices.
CONCLUSIONS: Antihypertensive prescribing patterns
are inconsistent with jNC-V guidelines. Actual practice
may deviate even more from these guidelines than re-
ported in this survey. Also, primary care physicians per-
ceive that managed care is increasingly affecting their pre-
scribing practices.
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MEDICAL AND ECONOMIC OUTCOMES IN
PATIENTS TREATED WITH DILTIAZEM OR
DIGOXIN FOR ATRIAL FIBRILLATION:
A DATABASE ANALYSIS
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This study compared the use and outcomes associated
with intravenous diltiazem and/or intravenous digoxin as
Abstracts
a primary therapy in patients admitted for treatment of
atrial fibrillation.
METHODS: A retrospective database analysis was con-
ducted with data from seven academic medical centers.
The use of intravenous diltiazem, digoxin, or both, in pa-
tients admitted for treatment of atrial fibrillation between
january 1993 and july 1996 was analyzed. SAS data sets
were created to combine financial records with clinical
files. The primary outcomes of interest measured were
the length of hospital stay (LOS), total hospital cost, hos-
pital mortality, and 30-day readmission rates.
RESULTS: A total of 107 patients was identified in the Uni-
versity Health System Consortium (UHC) clinical database
(CDB) with admissions for treatment of atrial fibrillation.
46, 41, and 20 patients received intravenous diltiazem,
digoxin, or both agents, respectively. Hospital mortality
rates were not different among patients. The most common
concomitant disease states included congestive heart failure
(n = 28) and hypertension (n = 9). The mean LOS was
4.11, 8.34, and 9.15 days for patients receiving diltiazem,
digoxin, or both agents, respectively. The mean total cost of
hospitalization was $4,890, $11,063 and $13,547 for pa-
tients receiving diltiazem, digoxin, or both agents, respec-
tively. More patients receiving both agents were readmitted
within 30 days (25%) as compared to patients receiving
only diltiazem (8%) or digoxin (22%).
CONCLUSION: Intravenous diltiazem was associated
with a decreased LOS, decreased total hospital costs, a
decreased 30-day readmission rate and no difference in
mortality in comparison with intravenous digoxin.
Therefore, intravenous diltiazem warrants further consid-
eration as a replacement for intravenous digoxin in the
cost-effective management of atrial fibrillation.
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Due to the recent changes in the strategies of treatment,
and the public health relevance of unstable angina (UA), it
is important to define epidemiology of interventions in or-
der to plan appropriate use of resources. The Italian Asso-
ciation of Hospital Cardiologists (ANMCO) planned to
conduct a registry on patients with acute coronary syn-
dromes (ACS).
METHODS: Data were collected at hospital discharge on
2,943 patients with ACS over 2 weeks (February 12-23,
1996) by 308 cardiological centers (81% of the existing
centers in Italy).
RESULTS: UA accounted for 1,420 cases (48%), while
AMI for 1,523 patients (52%). The length of stay of pa-
tients with UA was 9 ± 6 days; about half of them were
admitted to a CCU (length of stay 4 ± 3 days). Proce-
